Study Details

A study to evaluate the efficacy and safety of ASP5094 in patients with Rheumatoid Arthritis on methotrexate

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT03257852

Astellas Study ID

The unique identification code given by the study sponsor.

5094-CL-0201

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Condition

Rheumatoid Arthritis

Phase

These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2

Age

20 years - N/A

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Sep 2017 - Oct 2018

Masking

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Enrollment number

66

A Phase 2a, Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of ASP5094 in Patients with Rheumatoid Arthritis on Methotrexate

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A study to evaluate the efficacy and safety of ASP5094 in patients with Rheumatoid Arthritis on methotrexate? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site JP00024

Tsukuba, Japan

Site JP00018

Meguro, Japan

Site JP00012

Kanuma, Japan

Site JP00008

Fukuoka, Japan

Site JP00031

Yokohama, Japan

Site JP00006

Kyoto, Japan

Site JP00025

Kobe, Japan

Site JP00020

Nagano, Japan

Site JP00017

Tomakomai, Japan

Site JP00001

Sapporo, Japan

Site JP00013

Toyohashi, Japan

Site JP00004

Takasaki, Japan

Site JP00002

Asahikawa, Japan

Site JP00011

Oita, Japan

Site JP00009

Fukuoka, Japan

Site JP00027

Asahikawa, Japan

Site JP00010

Kumamoto, Japan

Site JP00007

Sanuki, Japan

Site JP00019

Sagamihara, Japan

Site JP00016

Ichinomiya, Japan

Site JP00023

Shimonoseki, Japan

Site JP00026

Fukuoka, Japan

Site JP00015

Chiba, Japan

Site JP00014

Nagoya, Japan

Site JP00003

Osaki, Japan

Site JP00028

Kawachinagano, Japan

Site JP00022

Okayama, Japan

Site JP00029

Beppu, Japan

Site JP00030

Kobe, Japan

Site JP00021

Shizuoka, Japan

Site JP00005

Kitamoto, Japan